237 filings
Page 4 of 12
6-K
il28oz
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
uutpbtayz1jpyinr7j
31 Aug 21
Current report (foreign)
4:30pm
6-K
q3vd27vf8ejwewoai
23 Aug 21
Current report (foreign)
4:30pm
6-K
p2ob903n8chw dc
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
g60 0itrk
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
k3z hm8sl
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
4wc04gl brbsze
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am
6-K
u9qtf
19 Jul 21
Current report (foreign)
4:30pm
6-K
qdq0bsly 6lx
2 Jul 21
Current report (foreign)
4:30pm
6-K
pba5w mu6xovrso2x0c
13 May 21
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
8:13am
6-K
pamblj1ecsdn hluhwav
3 May 21
China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis
8:42am
EFFECT
rmg5rmppyzgbp0afe
2 Apr 21
Notice of effectiveness
12:15am
CORRESP
zjz9r9z6pof
1 Apr 21
Correspondence with SEC
12:00am
UPLOAD
g9eq6uu29ev1fo
31 Mar 21
Letter from SEC
12:00am
6-K
fj1uzmal5oxchzqqvir
26 Mar 21
Current report (foreign)
5:11pm
F-3
vd02kpttkgqe1 tk
26 Mar 21
Shelf registration (foreign)
4:15pm
6-K
w96 4m24y
18 Mar 21
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
7:29am
6-K
cl9ma 42ad6y
16 Mar 21
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
8:38am
6-K
i6hk66v1
18 Feb 21
Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
9:26am